Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
前收盤價
US$141.33
−US$3.13 · -2.17%
盤中時間採用ET。市場資料可能有所延遲。
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
日內區間
目前US$141.33
52週區間
目前US$141.33
盤中時間採用ET。市場資料可能有所延遲。
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
日內區間
目前US$141.33
52週區間
目前US$141.33
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.06億 USD | 3.64億 USD | 3.05億 USD | 2.45億 USD | 1.88億 USD |
| 銷貨成本 | 1.25億 USD | 8574.2萬 USD | 6557.3萬 USD | 5512.6萬 USD | 4415.2萬 USD |
| 毛利 | 4.82億 USD | 2.78億 USD | 2.4億 USD | 1.9億 USD | 1.44億 USD |
| 研究與開發 | 7.71億 USD | 5.98億 USD | 5.71億 USD | 3.98億 USD | 2.73億 USD |
| 銷售、一般及管理費用 | 7.01億 USD | 4.61億 USD | 3.45億 USD | 2.66億 USD | 2.34億 USD |
| 營業費用 | 16.58億 USD | 11.56億 USD | 9.49億 USD | 6.48億 USD | 5.19億 USD |
| 利息收入 | 6065.6萬 USD | 5330.7萬 USD | 4213.2萬 USD | 1108.1萬 USD | 17.4萬 USD |
| 利息支出 | 8379.5萬 USD | 8491.3萬 USD | 8169.4萬 USD | 2644.6萬 USD | 4047.3萬 USD |
| 折舊和攤銷 | 1645萬 USD | 1101.3萬 USD | 1057.9萬 USD | 1033.1萬 USD | 1418.2萬 USD |
| 營業利益 | −11.77億 USD | −8.78億 USD | −7.1億 USD | −4.57億 USD | −3.75億 USD |
| 淨利 | −12.77億 USD | −9.14億 USD | −7.5億 USD | −4.82億 USD | −4.35億 USD |
公司資料更新於 2026年11月22日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6.16億0.03%6893億 USD0.03%US$340.02-3.52%
Vanguard Extended Market ETFVXF2.79億0.30%302億 USD0.05%US$211.44-3.21%
Vanguard Morningstar Small-Cap ETFVB2.76億0.15%787億 USD0.03%US$270.68-2.56%
Vanguard Morningstar Mid-Cap ETFVO2.63億0.12%1074億 USD0.03%US$76.25-2.22%
iShares Biotechnology ETFIBB2.35億2.25%105.27億 USD0.44%US$199.54-2.05%
Vanguard Morningstar Growth ETFVUG2.17億0.06%2210億 USD0.03%US$75.69-5.32%
iShares Russell Mid-Cap Growth ETFIWP1.71億1.04%163.65億 USD0.23%US$116.81-4.32%
State Street SPDR S&P Biotech ETFXBI1.7億1.76%96.36億 USD0.35%US$140.18-2.73%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Mid-Cap ETFVO
iShares Biotechnology ETFIBB
Vanguard Morningstar Growth ETFVUG
iShares Russell Mid-Cap Growth ETFIWP
State Street SPDR S&P Biotech ETFXBIAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。